enteropathy-associated T-cell lymphoma gluten intolerance
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - * 18 years old - Indication for a biopsy for the diagnosis or monitoring of: non-CD / non-inflamed, CD / non-inflamed, active CD, pre-EATL, EATL - Given informed consent
Exclusion criteria
Exclusion criteria: - No informed consent - Insufficient knowledge of Dutch language and/or inability to understand the information provided.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is currently unclear how the signalling pathways set off by TNF, IL-2 and IL-21 synergize to promote lymphoma growth. This project*s first goal is therefore to identify key signalling pathways activated by these cytokines and small-molecule inhibitors targeting these pathways. The efficacy of such inhibitors will be tested ex vivo using patient biopsies. This will allow a rational selection of drugs for future clinical trials, in which the predictive value of this ex vivo assay will also be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| Single-cell CyTOF: 1. Explore heterogeneity of the immune system between RCDII patients 2. Track the transition of the immune system in patients with celiac disease to patients with RCDII. Imaging CyTOF: 1. Validation of interesting immune cell subsets identified in single cell CyTOF 2. Look at immune cell composition in patients with CeD/RCDII. Single-cell RNA sequencing: 1. Explore heterogeneity of gene expression between patients with RCDII. FACS (sort), culture, cytotoxicity assays: 1. Functionality assays on immune cell subsets found to be specific for CeD/RCDII. | — |
Countries
Netherlands
Outcome results
None listed